Sponsored Links
| Treatment With Prolia(R) (Denosumab) Associated With Significantly Greater Adherence, Compliance And Persistence Compared To Alendronate |
 |
 |
 |
| Medical News - Compliance | |||
|
Amgen (NASDAQ:AMGN) today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis... Read more: Compliance News From Medical News Today
|